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Abstract
Purpose Secondary glaucoma is a difficult and frequent
complication of uveitis. The aim of this study is to describe
the results of surgery in uveitic glaucoma and to identify
situations linked to a high risk of failure of the surgery.
Methods Retrospective observational study. Clinical and
surgical data from 27 cases of uveitic glaucoma that
underwent glaucoma surgery over a period of 9 years were
collected.
Results The main diagnosis and aetiology were anterior
uveitis (61.90%) and herpes (38.10%) respectively. Trabe-
culectomy with mitomycin C was performed in 51.9% of
the cases. An intraocular pressure lower than 16 mmHg and
managed with less than two drugs was achieved in 48.15%
of the cases. Higher risks of surgical failure were associated
with intermediate uveitis, idiopathic uveitis, Fuchs’ cyclitis,
combined surgery with phacoemulsification, omission of
mitomycin C, intraocular inflammation at surgery and
relapse of the uveitis.
Conclusions There are some situations linked to a high risk
of failure of surgery in uveitic glaucoma, which should be
avoided when possible, mainly the association of higher
risk with combined approaches.
Keywords Glaucoma.Glaucoma surgery.Mitomycin C.
Trabeculectomy.Uveitis
Introduction
Secondary uveitic glaucoma is a common complication of
intraocular inflammation and is present in up to 20% of
patients with uveitis [1, 2]. Several mechanisms are
involved in the pathogenesis of uveitic glaucoma [1].
Uveitic glaucoma often gets worse despite intensive
medical treatment, and it may require surgical intervention.
Surgical management is challenging because of the in-
creased risk of post-operative inflammation and failure to
control intraocular pressure (IOP) [3]. The aim of this study
was to analyse the different variables that play a role in the
final surgical outcome of uveitic glaucoma in a cohort of
patients with intraocular inflammatory disease attending a
referral centre.
Materials and methods
All patients with uveitic glaucoma who underwent glauco-
ma surgery at the Hospital Clínico Universitario de
Valladolid over a period of 9 years (1999–2007) were
reviewed. All procedures conformed to the tenets of the
Declaration of Helsinki, and the study was approved by the
Institutional Review Board of that hospital. Data collected
from clinical charts included age, sex, affected eye,
predominant anatomic location of inflammation, aetiology,
course, time of follow-up, time between the diagnosis of
uveitis and the diagnosis of glaucoma, time between the
diagnosis of glaucoma and the surgery, state of the angle at
time of surgery, pre- and post-surgical visual acuity and
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of anti-metabolites, flare-up of uveitis after surgery,
complications, necessity for a second surgery, final out-
come, and where relevant, time to the failure. A case was
considered as one surgical procedure for glaucoma; thus the
same eye could be considered as two separate cases if re-
intervention was necessary.
Uveitis was diagnosed based on clinical examination.
Types of uveitis, anatomic classification, and course were
defined according to the criteria proposed by the International
Uveitis Study Group [4] and by aetiology [5]. Patients were
considered to have uveitic glaucoma if there was no previous
history of glaucoma or IOP higher than 21 mmHg prior to
the onset of uveitis. Furthermore, after diagnosis of uveitis,
the patients developed an IOP higher than 21 mmHg that
required anti-glaucoma treatment and optic disc abnormali-
ties characteristic of glaucoma. For the patients in this study,
the IOP was not controlled by topical medication and/or
there was evidence of deterioration of glaucoma defined by
worsening of the visual field, indicating the need for surgery.
One week prior to surgery, all the patients got 40 mg of
transeptal triamcinolone. Beginning 3 days before surgery,
patients were given dexamethasone eyedrops every 2 h to
prevent flare-up. If required, basal treatment of the uveitis
was maintained. Post-surgical treatment consisted of a
commercial combination of dexamethasone and antibiotic
(tobramicine or neomicine sulfate plus polimixine-B-
sulfate) eye drops every 2 h for the first week with tapering
thereafter as needed.
Surgical procedures included trabeculectomy, phacotra-
beculectomy, and Ahmed valve implantation. For each type
of surgery, some cases were treated with the anti-metabolite
mitomycin C (MMC). The concentration of MMC was
determined according to the risk of the surgery (Table 1),
the cases were MMC was not used are previous cases to the
application of this protocol [6]. A 3×5 mm piece of sponge
(Espongostan Film, Ferrosan A/S, Copenhagen, Denmark)
soaked with MMC was placed under the conjunctival flap
over the scleral bed in trabeculectomy and over the plate in
sub-Tenon space in Ahmed valve for 2 min. Subsequently,
the sponge was removed and it was copiously irrigated with
balanced salt solution. Trabeculectomy was performed with
the limbus-base technique, and phacoemulsification was
achieved with a clear corneal incision and intraocular lens
implantation. All surgeries were executed by the same
surgeon (J.A.M.) and most occurred after at least 6 months
of inflammation control. In a few cases, it was imperative to
control the IOP even though the intraocular inflammation
was not fully under control. Follow-up visits were held on
days 1–3 post-surgery, then weekly until 1 month after the
surgery. Visits were then held monthly until 3 months after
surgery and then every 3 months until 1 year after surgery.
After that, follow-up visits were held every 6 months unless
complications arose.
Outcomes were measured by changes in visual acuity
and IOP with or without anti-glaucoma medication.
Changes in visual acuity were defined as increases or
decreases of ≥1 line in Snellen charts from the initial best-
Risk factor Assigned risk MMC concentration (mg/ml)
Previous surgery (conjunctiva) 6
Combined surgery 5
Secondary glaucoma 4
Target IOP<16 mmHg 4
Topical treatment >1 year 3
Age<40 years 3
Diabetes melitus 1
Previous laser trabeculoplasty 1
<2 No MMC
3–5 0.1
6–9 0.2
>10 0.4
Table 1 Protocol to select
MMC concentration
Case First procedure Second procedure Third procedure Final outcome
1 Trabeculectomy+MMC Ahmed valve+MMC Partial success
2 Trabeculectomy+MMC Ahmed valve Total success
3 Phacotrabeculectomy+MMC Trabeculectomy+MMC Ahmed valve Total success
4 Phacotrabeculectomy Trabeculectomy+MMC Ahmed valve Failure
Table 2 Procedures and final
outcome of patients who needed
re-surgery
44 J Ophthal Inflamm Infect (2011) 1:43–53corrected visual acuity. IOP was measured with a Goldman
applanation tonometer.
The final outcome after surgerywas classifiedas: complete
success (IOP ≤16 mmHg with no drugs or only one drug for
control), partial success (IOP ≤16 mmHg with ≥2 drugs for
control) and failure (IOP >16 mmHg). The value of IOP
considered for final outcome was the value recorded at the
patient’s last visit during the study period.
All the data were collected in an Access database
(Microsoft Office Access 2007, Microsoft Corporation,
Redmond, WA, USA) and further analysed by SPSS (SPSS
version 15.0, SPSS Inc., Chicago, IL, USA). Descriptive
analyses were performed, and statistics were presented as
means±standard deviations and as 99.61% confidence
Table 3 Relationship between final outcome, visual acuity and age
n/27 (%) Age
a
Final outcome
Complete success 13/27 (48%) 49.77±16.50
Partial success 3/27 (11%) 61.67±17.04
Failure 11/27 (41%) 42.40±9.69
Visual acuity
Improved 15/27 (56%) 48.73±14.77
Unchanged 5/27 (18%) 48.50±19.96
Worsened 7/27 (26%) 47.28±14.97
aMean±standard deviation
Table 4 Anatomic classification, aetiology and course of uveitic
disease
Number Per cent
Anatomic classification
Anterior uveitis 13 62
Intermediate uveitis 5 24
Panuveitis 3 14
Uveitis aetiology
Herpes 8 38
Fuchs’ heterochromic cyclitis 3 14
Ankylosing spondylitis 3 14
Tuberculosis 2 10
Anterior idiophatic 1 5
Behçet’s disease 1 5
Pars planitis 1 5
Posner–Schlossman syndrome 1 5
Sarcoidosis 1 5
Course of uveitis
Recurrent 13 62
Chronic 8 38
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48 J Ophthal Inflamm Infect (2011) 1:43–53intervals (CI 99.61%), according with Bonferroni correc-
tion for an α=0.05.
Results
Data were collected from 19 patients with a total of 21
eyes. Including surgeries on the same eye, there were 27
cases (in two cases, one re-surgery and in two cases, two re-
surgeries, Table 2 resume the cases where a re-intervention
was needed). There were no significant differences in
gender (11 males; eight females) and laterality (13 right
eyes; 14 left eyes). The mean age was 48.3±15.0 years
(mean±SD), and the mean follow-up period was 69.6±
54.9 months (range, 8–204 months). Age was not a factor
in the final outcome and visual acuity (Table 3). Most of the
patients (61.90%) had anterior uveitis (Table 4). Eight of
the uveitis were due to herpes infection (38.10%), followed
by Fuchs’ cyclitis (14.29%) and ankylosing spondylitis
(14.29%) (Table 4).
Twenty-two cases (81.5%) took >1 year from the
diagnosis of the uveitis to glaucoma. For 21 cases, >1 year
elapsed between the diagnosis of the glaucoma and surgery.
Twenty-three cases (85.2%) had open angles before
surgery, and two (7.4%) had closed angles. In one case,
the angle was open with synechiaes, and in another case
there was an iris plateau. In two cases, elevated IOP
necessitated glaucoma surgery before inflammation was
under control.
Trabeculectomy with MMC was performed in 14 cases
(51.9%) while six cases had combined phacoemulsification
and trabeculectomy (five with MMC (18.5%) and one
without MMC (3.7%)) and seven cases had Ahmed valve
insertions (six without MMC (22.2%), and one with MMC
(3.7%)). Re-intervention was needed in 12 cases (44.4%),
with no statistically significant relationship to either
anatomic classification or aetiology.
Complete success was achieved in 13 cases (48.2%),
partial success in three cases (11.1%), and failure occurred
in 11 cases (40.7%). The mean time from surgery to failure
was 47.5±58.7 months (range, 4–192 months). Most
failures (36.4%) occurred during the first year of follow-
up while 27.3% occurred during the second year and
36.36% after >5 years of follow-up.
The pre-surgical IOP was 31.9±9.9 mmHg (CI 95%,
28.0–35.7 mmHg), and the post-surgical IOP for all cases at
the end of the follow-up period was 17.3±9.1 mmHg (CI
95%, 13.8–20.8). The visual acuity increased after surgery
in 15 cases (55.6%) and decreased in seven cases (25.9%).
It remained stable in five cases (18.5%). There was no
correlation between outcomes of visual acuity and IOP.
In most cases, there was also no correlation in the final
IOP outcome or visual acuity according with the anatomic
T
a
b
l
e
1
2
F
i
n
a
l
I
O
P
o
u
t
c
o
m
e
a
n
d
v
i
s
u
a
l
a
c
u
i
t
y
a
c
c
o
r
d
i
n
g
t
o
t
h
e
r
e
l
a
p
s
e
o
f
t
h
e
u
v
e
i
t
i
s
F
i
n
a
l
I
O
P
o
u
t
c
o
m
e
V
i
s
u
a
l
a
c
u
i
t
y
C
o
m
p
l
e
t
e
s
u
c
c
e
s
s
P
a
r
t
i
a
l
s
u
c
c
e
s
s
F
a
i
l
u
r
e
I
m
p
r
o
v
e
m
e
n
t
U
n
c
h
a
n
g
e
d
W
o
r
s
e
n
i
n
g
n
(
%
)
I
C
(
9
9
.
6
1
%
)
n
(
%
)
I
C
(
9
9
.
6
1
%
)
n
(
%
)
I
C
(
9
9
.
6
1
%
)
n
(
%
)
I
C
(
9
9
.
6
1
%
)
n
(
%
)
I
C
(
9
9
.
6
1
%
)
n
(
%
)
I
C
(
9
9
.
6
1
%
)
R
e
l
a
p
s
e
o
f
u
v
e
i
t
i
s
1
(
2
0
)
0
–
7
2
%
0
(
0
)
–
4
(
8
0
)
2
8
–
1
0
0
%
5
(
1
0
0
)
–
0
(
0
)
–
0
(
0
)
–
N
o
r
e
l
a
p
s
e
o
f
u
v
e
i
t
i
s
1
2
(
5
5
)
2
5
–
8
5
%
3
(
1
4
)
0
–
3
5
%
7
(
3
2
)
9
–
5
5
%
1
0
(
4
5
)
1
6
–
7
4
%
5
(
2
3
)
9
–
3
7
%
7
(
3
2
)
9
–
5
5
%
J Ophthal Inflamm Infect (2011) 1:43–53 49classification (Table 5). The exception was for panuveitis
where all three cases were total successes with regard to
IOP management, and two of them had improved visual
acuity. With regard to aetiology, the final IOP outcome was
worst for anterior idiopathic uveitis, where all cases failed,
and for Fuchs’ cyclitis, where most of the cases failed
(Table 6), although these differences were not statistically
significant in the second case. However, in relation with the
aetiology and course of the uveitis, there were neither
significant differences in the final visual acuity nor IOP
outcome (Table 7).
There was no statically difference in success or visual
acuity according to the surgical procedure (Table 8), to the
interval between the diagnosis of uveitis and glaucoma or
the time between the diagnosis of glaucoma and surgery
(Tables 9 and 10).
The interval between diagnosis of uveitis and glaucoma
was significantly correlated with the interval between diag-
nosis of glaucoma and surgery (Fisher’s exact test, p=0.028).
Thus, longer times before the onset of glaucoma were
associated with longer times to surgery.
All cases of active uveitis at the time of surgery failed. In
contrast just 36% of cases of inactive uveitis at the time of
surgery failed. Similarly, the visual acuity worsened in 50%
of active uveitis, but just in 24% of inactive uveitis
(Table 11).
Relapse of the uveitis increases the risk of failure of the
surgery, although the differences were not statistically
significant (Table 12).
Treatment with MMC had a mild positive effect on the
rate of complete success and improved visual acuity, but
without a statistical significant difference (Table 13).
The combination of glaucoma and cataract surgery had a
negative effect on the complete success rate, but not in
visual acuity, although there were not statistical significant
differences (Table 14).
The second procedures had a higher risk of failure in
comparison with first procedures, although these differ-
ences were not statistically significant (Table 15).
Post-surgical complications included 1case each of
macular edema, epiretinal membrane, endothelial injury,
papillary and macular haemorrhage, subluxation of the
intraocular lens and retinal detachment. There were two
cases each of hyphema and diffuse bleb. There were
four cases each of cystic bleb, encapsulated bleb, and
plane bleb. Finally there were six cases of avascular
bleb. Some cases had >1 complication and seven had no
complications.
Discussion
Estimates of the prevalence of various types of uveitis
are highly variable, depending on if the data are based on
cases seen at tertiary referral centres or at community-
based centres. The geographic location of the study also
produces different results, depending on numerous
factors. The estimated prevalence in the Spanish popula-
tion for each type of uveitis by anatomic classification is
around 50.2%, 10.1%, 29.6% and 10.1% for anterior,
intermediate, posterior uveitis and panuveitis, respective-
ly [7].
Although some authors report no differences in the
incidence of uveitic glaucoma in relation to anatomic
classification and aetiology [8], our results agree with
others that established anterior uveitis as the main cause of
uveitic glaucoma, although only 5% of anterior uveitis
patients are affected [9]. The majority of cases in our study
(61.90%) were due to anterior uveitis, which is consistent
with the overall distribution of uveitis. Twenty-four per
cent (23.81%) of our cases were due to intermediate
uveitis, about twice the prevalence in the uveitis popula-
tion. This suggests that intermediate uveitis could be a
high risk factor for the development of glaucoma and the
consequent need for surgery. There were no cases of
posterior uveitis in this study, although its prevalence in
uveitis population is around 10.1%. Thus there is only a
low likelihood of developing secondary uveitic glaucoma
as a result of posterior uveitis. This is probably because
the aqueous outflow pathway is less influenced by
posterior segment inflammation, and the prevalence of
IOP elevation is lower in posterior uveitis. For panuveitis,
Table 13 Final IOP outcome and visual acuity according to the use of anti-metabolites (mitomycin C (MMC))
Final IOP outcome Visual acuity
Complete success Partial success Failure Improvement Unchanged Worsening
n (%) IC
(99.61%)
n (%) IC
(99.61%)
n (%) IC
(99.61%)
n (%) IC
(99.61%)
n (%) IC
(99.61%)
n (%) IC
(99.61%)
MMC 10 (50) 18–82% 3 (15) 0–41% 7 (48) 17–79% 12 (60) 28–92% 5 (25) 0–53% 3 (15) 0–41%
No MMC 3 (43) 0–97% 0 (0) – 4 (57) 3–100% 3 (43) 0–97% 0 (0) – 4 (57) 3–100%
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J Ophthal Inflamm Infect (2011) 1:43–53 51the percentage of cases developing uveitic glaucoma in
our study was similar to the prevalence of uveitis in the
population.
The main causes of uveitic glaucoma are juvenile
chronic arthritis [10], Fuchs’ cyclitis [11, 12], Posner–
Schlossman syndrome [2] and herpetic keratouveitis [13].
However, we found that the greatest risk factor for
glaucoma surgery was associated with herpes, Fuchs’
cyclitis and ankylosing spondylitis. The differences be-
tween our findings and those reported by others could be
that the main causes of uveitic glaucoma are not the ones
that usually lead to glaucoma surgery.
Anterior idiopathic uveitis and Fuchs’ cyclitis were
associated with a higher risk for failure of surgery. The
absence of a satisfactory treatment for anterior idiopathic
uveitis makes it difficult to manage. This in turn makes
the medical treatment of glaucoma more difficult and
increases the probability of failure of surgery. A portion
of the patients with Fuchs’ cyclitis remains asymptom-
atic for a longer period than with other forms of uveitis.
This may result in a relative underdiagnosis of the
syndrome and perhaps an overestimate of the true
frequency of secondary glaucoma resulting from it. In
any case, when Fuchs’ cyclitis is complicated by
glaucoma, it has a higher risk of requiring surgery and
ah i g hr i s ko ff a i l u r e .
A previous report showed that 26% of the eyes with
chronic uveitis developed secondary glaucoma, compared
with only 12% of the eyes with acute uveitis [14].
However, we found that most of the surgeries were
associated with acute, recurrent uveitis. The increased
prevalence of glaucoma in chronic uveitis reflects the
accumulated detrimental effects of inflammation and
probably the consequence of chronic corticosteroid therapy
on an initially normal trabecular meshwork [15, 16].
However the higher rate of secondary glaucoma was not
accompanied by a higher rate of glaucoma surgery [13]i n
contrast with our study where acute-recurrent uveitis was
the main cause of glaucoma surgery.
The results were worse when surgery was necessitated
prior to control of the intraocular inflammatory disease.
Good control of intraocular inflammation for a minimum of
3 months before surgery is ideal but may not be practical
because glaucoma surgery in uveitis is rarely performed on
an elective basis. Similarly the relapse of the uveitis after
the surgery was associated with a higher percentage of
failure. So the control of the inflammatory process is crucial
not only before of surgery but also after it to achieve a
success.
Trabeculectomy has traditionally been the surgical
procedure of choice for managing medically uncontrolled
IOP in patients with uveitis. Previous reports have
demonstrated a significant increase in the long-term success
of trabeculectomy with anti-metabolic agents such as
intraoperative application of MMC and intraoperative and
post-operative 5-fluorouracil [17–20]. Our results with
MMC are consistent with these reports.
The success rate for combined phacoemulsification and
trabeculectomy approaches that of trabeculectomy alone
[21]. However, there are studies reporting that trabeculec-
tomy alone is better than the combined surgeries [22]. In
our study, we found worse results with the combined
surgery than with trabeculectomy alone, which seems to
cause less post-operative flare than cataract surgery in
isolation [23], possibly explaining the better success of
trabeculectomy alone in primary open-angle glaucoma than
the combined surgery [24]. It is likely that this effect is
exaggerated in uveitis, and the combined cataract and
glaucoma surgery may not be appropriate. Although some
studies reported good outcomes combined phacoemulsifi-
cation approaches in uveitic glaucoma [25], however, there
are no prospective studies which compare the success rate
for combined phacoemulsification and trabeculectomy
approaches in uveitic glaucoma, so further studies are
warranted.
Repeat surgery is less successful at achieving IOP
reduction in open-angle glaucoma than is initial surgery at
3 years or more [26]. This is consistent with the results of
this study in the case of uveitic glaucoma, where also a re-
surgery was associated with a higher risk of failure.
In other series of surgery in uveitic glaucoma the rates
of failure of the surgery in uveitic glaucoma are
comparable, with a higher incidence of failure associated
with longer follow-up [25, 27, 28]. Although the
comparison becomes difficult because of the variability
among studies to define success and the fact that in this
study a lot of factors were taking into account, so further
prospective and controlled studies are warranted in order
to define the correct management of uveitic glaucoma. It
has been reported a good outcome in uveitic glaucoma
managed with trabeculectomy [25, 27, 28]a n da l s ow i t h
Ahmed valve [29, 30], and although in this study it was
not found differences between both approaches, there is
not studies which compare trabeculectomy and Ahmed
valve in the case of uveitic glaucoma. The new aproaches
such as deep sclerectomy have been also applied in the
case of uveitic glaucoma without significative differences
with traditional trabeculectomy, although a longer follow-
up would be warranted specially in the case of uveitic
glaucoma [31].
This study has the limitations of a retrospective study.
Further analysis in prospective studies will help to decide
the correct management for glaucoma that is secondary to
the different types of uveitis. Also studies with higher
population should be performed in order to increase the
statistic power.
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